Analyst John Newman from Canaccord Genuity maintained a Buy rating on 2seventy bio (TSVT – Research Report) and keeping the price target at $12.00. John Newman has given his Buy
Analyst John Newman from Canaccord Genuity maintained a Buy rating on 2seventy bio (TSVT – Research Report) and keeping the price target at $12.00. John Newman has given his Buy
Citi raised the firm’s price target on 2seventy Bio to $12 from $9 and keeps a Buy rating on the shares after the FDA approved Abecma for 3L+ multiple myeloma
2seventy bio (TSVT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on April 5. Analyst Samantha Semenkow from Citi maintained a Buy rating on
An update from 2seventy bio (TSVT) is now available. 2seventy bio, Inc. and Bristol Myers Squibb have announced the FDA approval of Abecma, a new treatment for adult patients with
Bristol Myers Squibb (BMY) and 2seventy bio (TSVT) have announced that on April 4, 2024, the U.S. Food and Drug Administration, FDA, approved Abecma for the treatment of adult patients